Eliquis, a new oral direct Factor Xa inhibitor, has received European Commission approval for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.

The approval of Eliquis is based on three clinical trials that showed that, when given orally twice daily, it demonstrated superior efficacy and decreased the risk of bleeding compared to enoxaparin.

Developed in collobaration with Bristol-Myers Squibb and Pfizer, Eliquis, an oral anticoagulant with a 12-to-24-hour post surgery initiation window, helps physicians observe and stabilise post-surgical patients before beginning treatment.

Glostrup Hospital MD Michael Rud Lassen said that total knee replacement or total hip replacement puts patients at a very high risk of developing venous thromboembolic events or a pulmonary embolism.

He added that Eliquis gives European orthopaedic surgeons a new option in venous thromboembolic event prevention that is more effective than the current standard of care.